FFAR3

Free fatty acid receptor 3 · O14843 · FFAR3 on Sugi Atlas →

30,166 patent compounds predicted against FFAR3, 17,875 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Propionic Acid (SCHEMBL81542)	0.67	4/20
SCHEMBL8158	0.47	4/20
SCHEMBL181996	0.43	4/20
Tetrylammonium (SCHEMBL168442)	0.39	4/20
Butyric Acid (SCHEMBL26687)	0.93	3/20
Butyric Acid (SCHEMBL59801)	0.93	3/20
Butyric Acid (SCHEMBL60746)	0.93	3/20
Butyric Acid (SCHEMBL112217)	0.93	3/20
Butyric Acid (SCHEMBL123022)	0.93	3/20
Butyric Acid (SCHEMBL132506)	0.93	3/20
Butyric Acid (SCHEMBL162471)	0.93	3/20
Butyric Acid (SCHEMBL191217)	0.93	3/20
Butyric Acid (SCHEMBL192173)	0.93	3/20
Butyric Acid (SCHEMBL24420)	0.87	3/20
Cyclohexane (SCHEMBL175231)	0.70	3/20
Succinic Acid (SCHEMBL143984)	0.67	3/20
Propionic Acid (SCHEMBL181843)	0.67	3/20
Acetic Acid (SCHEMBL139024)	0.64	3/20
SCHEMBL108642	0.62	3/20
Succinic Acid (SCHEMBL35204)	0.58	3/20

Clinical trials — most relevant to FFAR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)	PHASE4	COMPLETED
Fat, Inflammation and Insulin Resistance	PHASE4	COMPLETED
Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes	PHASE4	COMPLETED
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome	PHASE2/PHASE3	COMPLETED
Omega 3 Supplementation in Fatty Liver	PHASE3	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Regional Lipolysis Insulin Regulation	EARLY_PHASE1	RECRUITING
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
Colonic Propionate, Appetite, and Weight Loss	nan	COMPLETED
Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis	nan	WITHDRAWN
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Growth Hormone Signaling in Vivo in Humans	nan	COMPLETED
Molecular Pathways Related to Short-term Fasting Response	nan	COMPLETED
Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus	nan	COMPLETED
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients	nan	COMPLETED
FFA Hypertension and Inflammation in Lean and Obese Subjects	nan	COMPLETED
Hepatic Metabolic Changes in Response to Glucagon Infusion	nan	COMPLETED
The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity	nan	COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients	nan	COMPLETED
Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6	nan	COMPLETED
Study of Changes in Skeletal Muscle After Caloric Restriction	nan	ACTIVE_NOT_RECRUITING
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Gut Microbiota and Modulation of Liver Damage in NAFLD	nan	COMPLETED
Production of Free Fatty Acids From Blood Triglycerides	nan	COMPLETED
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FFAR3 binder may also engage these)

Protein	Name	Similarity
O15529	—	1.000	O15529 →
B2GV46	—	0.993	B2GV46 →
Q3UFD7	—	0.993	Q3UFD7 →
FFAR2	Free fatty acid receptor 2	0.991	landscape →
Q76EI6	—	0.984	Q76EI6 →
Q8VCK6	—	0.984	Q8VCK6 →
Q76JU9	—	0.982	Q76JU9 →
O46685	—	0.980	O46685 →
Q920E0	—	0.980	Q920E0 →
Q8BUD0	—	0.979	Q8BUD0 →
GPR68	G-protein coupled receptor 68	0.978	landscape →
Q8C131	—	0.977	Q8C131 →
Q149R9	—	0.977	Q149R9 →
Q9Z282	—	0.977	Q9Z282 →
O00590	—	0.976	O00590 →
GPR132	Probable G-protein coupled receptor 132	0.976	landscape →
OXER1	Oxoeicosanoid receptor 1	0.976	landscape →
Q8K3T4	—	0.976	Q8K3T4 →
Q6NS65	—	0.976	Q6NS65 →
Q09QM4	—	0.976	Q09QM4 →
O09027	—	0.976	O09027 →
Q8BYC4	—	0.975	Q8BYC4 →
Q99678	—	0.975	Q99678 →
Q86VZ1	—	0.975	Q86VZ1 →
Q3ZC80	—	0.974	Q3ZC80 →
GPR17	Uracil nucleotide/cysteinyl leukotriene receptor	0.974	landscape →
Q8BFQ3	—	0.974	Q8BFQ3 →
Q76JU8	—	0.973	Q76JU8 →
GPR55	G-protein coupled receptor 55	0.973	landscape →
Q9ES90	—	0.973	Q9ES90 →